Press releases
Nov 13, 2023
SUNSHINE BIOPHARMA REPORTS 2023 THIRD QUARTER RESULTS: REVENUES UP SIGNIFICANTLY OVER LAST YEAR DUE TO A KEY ACQUISITION
Sep 21, 2023
SUNSHINE BIOPHARMA RECEIVES 180-DAY EXTENSION TO ACHIEVE NASDAQ MINIMUM BID COMPLIANCE
Aug 11, 2023
SUNSHINE BIOPHARMA REPORTS 2023 SECOND QUARTER RESULTS: REVENUES UP 3,600%
May 16, 2023
SUNSHINE BIOPHARMA ANNOUNCES CLOSING OF $5.0 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET
May 12, 2023
SUNSHINE BIOPHARMA ANNOUNCES PRICING OF $5.0 MILLION PRIVATE PLACEMENT PRICED AT THE MARKET
May 11, 2023
SUNSHINE BIOPHARMA REPORTS 2023 FIRST QUARTER RESULTS: REVENUES UP 2,100%
Apr 05, 2023
SUNSHINE BIOPHARMA REPORTS FULL YEAR ENDED DECEMBER 31, 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Feb 28, 2023
SUNSHINE BIOPHARMA SIGNS EXCLUSIVE WORLDWIDE LICENSE WITH UNIVERSITY OF ARIZONA FOR PLpro-BASED COVID-19 TREATMENT
Feb 10, 2023
SUNSHINE BIOPHARMA SIGNS RESEARCH AGREEMENT WITH THE JEWISH GENERAL HOSPITAL TO ADVANCE THE DEVELOPMENT OF Adva-27a ANTICANCER COMPOUND
Jan 19, 2023
SUNSHINE BIOPHARMA ANNOUNCES SHARE REPURCHASE PROGRAM
Dec 20, 2022
SUNSHINE BIOPHARMA’S ANNUAL LETTER TO SHAREHOLDERS
Nov 16, 2022
SUNSHINE BIOPHARMA ENTERS INTO COLLABORATION WITH A LEADING LIPID NANOPARTICLE FORMULATION COMPANY FOR ITS K1.1 ANTICANCER mRNA PROJECT
Oct 20, 2022
SUNSHINE BIOPHARMA ANNOUNCES THE ACQUISITION OF NORA PHARMA, ADDING $10.7 MILLION IN REVENUE
Jul 28, 2022
SUNSHINE BIOPHARMA INCREASES SUPPORT FOR ANTI-CORONAVIRUS COLLABORATIVE RESEARCH WITH THE UNIVERSITY OF ARIZONA
Apr 28, 2022
Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market
Apr 26, 2022
Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market
Apr 25, 2022
Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules…
Apr 05, 2022
Sunshine Biopharma’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells
Mar 14, 2022
Sunshine Biopharma, Inc. Announces Closing of $8.0 Million Private Placement Priced At-the-Market
Mar 10, 2022
Sunshine Biopharma, Inc. Announces Pricing of $8.0 Million Private Placement Priced At-the-Market
Feb 25, 2022
SUNSHINE BIOPHARMA EXPANDS ANTI-CORONAVIRUS DRUG DEVELOPMENT PROGRAM BY SIGNING A COLLABORATION AGREEMENT WITH THE UNIVERSITY OF ARIZONA
Feb 15, 2022
Sunshine Biopharma Inc. Announces Pricing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market
Dec 22, 2021
Sunshine Biopharma Announces $1,361,000 in Debt Reduction
Nov 03, 2021
SUNSHINE BIOPHARMA EXPANDS BOARD OF DIRECTORS
Oct 06, 2021
Sunshine Biopharma Files a Patent Application Covering mRNA Molecules…
Aug 12, 2021
SUNSHINE BIOPHARMA’S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST DELTA AND THE OTHER VARIANTS OF CONCERN
Jul 27, 2021
Sunshine Biopharma Opens Twitter Account For Increased Shareholder Engagement
Jul 20, 2021
SUNSHINE BIOPHARMA RECEIVES $0.9 MILLION IN ADDITIONAL FUNDING FROM RB CAPITAL
Jul 08, 2021
Sunshine Biopharma Employs mRNA Vaccine Technology to Expand Its Fight Against Multidrug Resistant Cancer
Jun 09, 2021
SUNSHINE BIOPHARMA MICE STUDY FOR COVID-19 TREATMENT PROGRESSING AS PLANNED
May 20, 2021
SUNSHINE BIOPHARMA ELIMINATES $250,000 IN VARIABLE RATE CONVERTIBLE DEBT AND PROVIDES AN UPDATE ON STATUS OF OTCQB UPLISTING
May 13, 2021
SUNSHINE BIOPHARMA REPORTS IMPROVED CASH POSITION IN 2021Q1 FILING
May 04, 2021
SUNSHINE BIOPHARMA UPGRADES COVID-19 PROVISIONAL PATENT APPLICATION TO FULL PCT APPLICATION
Apr 23, 2021
SUNSHINE BIOPHARMA REPORTS FAVORABLE MTD RESULTS FOR COVID-19 TREATMENT
Apr 22, 2021
RB CAPITAL INCREASES INVESTMENT IN SUNSHINE BIOPHARMA
Mar 23, 2021
SUNSHINE BIOPHARMA REACHES $2,000,000+ FINANCING FOR CORONAVIRUS TREATMENT
Mar 11, 2021
SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a IN EUROPE UNTIL 2033
Mar 04, 2021
Sunshine Biopharma Receives Recently Ordered New Batch of Adva-27a And Initiates QA/QC Testing
Mar 01, 2021
Sunshine Biopharma Launches Online Store for Its Science-Based Nutritional Supplements
Feb 18, 2021
Sunshine Biopharma Discusses The Progress of Its COVID-19 and Anticancer Compounds with The Stock Day Podcast
Feb 10, 2021
SUNSHINE BIOPHARMA INITIATES COVID-19 TREATMENT MICE STUDY
Feb 04, 2021
SUNSHINE BIOPHARMA SIGNS EXCLUSIVE LICENSE AGREEMENT WITH UNIVERSITY OF GEORGIA FOR COVID-19 COMPOUNDS
Feb 02, 2021
SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a IN CANADA UNTIL 2033
Jan 27, 2021
SUNSHINE BIOPHARMA COMPLETES APPLICATION TO UPLIST TO OTCQB
Jan 14, 2021
SUNSHINE BIOPHARMA RECEIVES FOURTH TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT
Dec 22, 2020
SUNSHINE BIOPHARMA’S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST THE NEW VARIANT IDENTIFIED IN THE UK
Dec 08, 2020
SUNSHINE BIOPHARMA ORDERS A NEW BATCH OF Adva-27a FOR TESTING ON TOPII AMPLIFIED CANCERS
Dec 03, 2020
SUNSHINE BIOPHARMA PAYS OFF CONVERTIBLE NOTES IN CASH PREVENTING NEW SHARES FROM HITTING THE MARKET
Dec 01, 2020
SUNSHINE BIOPHARMA RECEIVES THIRD TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 plus FINANCING FOR CORONAVIRUS TREATMENT
Nov 24, 2020
SUNSHINE BIOPHARMA BELIEVES THAT AN EFFECTIVE CORONAVIRUS TREATMENT CONTINUES TO BE NECESSARY
Nov 18, 2020
Sunshine Biopharma Signs An Agreement With A Montreal-Based Company To Advance The Development Of Adva-27a Anticancer Compound
Nov 10, 2020
Sunshine Biopharma Signs an Agreement for Distribution of Essential-9TM in Asia and the Far East
Oct 26, 2020
SUNSHINE BIOPHARMA RECEIVES SECOND TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT
Oct 19, 2020
SUNSHINE BIOPHARMA AND UNIVERSITY OF GEORGIA TEAM UP TO DEVELOP A NEW ANTI-CORONAVIRUS DRUG
Oct 07, 2020
SUNSHINE BIOPHARMA IDENTIFIES A LEAD ANTI-CORONAVIRUS COMPOUND
Sep 15, 2020
SUNSHINE BIOPHARMA SECURES $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT
Aug 25, 2020
SUNSHINE BIOPHARMA COMPLETES THE SYNTHESIS OF FOUR POTENTIAL INHIBITORS OF CORONAVIRUS PROTEASE
Jun 03, 2020
SUNSHINE BIOPHARMA FILES A PATENT APPLICATION FOR A NEW CORONAVIRUS COVID-19 TREATMENT
Nov 06, 2019
SUNSHINE BIOPHARMA RECEIVES HEALTH CANADA APPROVAL FOR ESSENTIAL CALCIUM-VITAMIN DTM SUPPLEMENT
Oct 17, 2019
SUNSHINE BIOPHARMA INITIATES Adva-27a XENOGRAFT STUDIES IN MICE CARRYING DIFFERENT TYPES OF HUMAN CANCER<
Sep 03, 2019
Sunshine Biopharma Receives Vegan Certification for Essential 9™ Amino Acids Supplement
May 28, 2019
In Addition to Essential 9™, Sunshine Biopharma Launches 7 New Dietary Supplements Now Available on Amazon.ca
May 16, 2019
Sunshine Biopharma Announces that Essential 9™ is Now Available in the United States on Amazon.com
Mar 12, 2019
SUNSHINE BIOPHARMA ANNOUNCES THAT ESSENTIAL 9™ IS NOW AVAILABLE ON AMAZON.CA
Feb 04, 2019
Sunshine Biopharma Receives Notice Of Allowance For A New Patent Application Extending Protection Of Adva-27a Anticancer Drug Until 2033
Dec 17, 2018
Sunshine Biopharma Receives Health Canada Approval for Essential 9™, The Company’s First Over The Counter Essential Micronutrient
Dec 12, 2018
Sunshine Biopharma Signs an Agreement With Crocus Laboratories for Manufacturing of Adva-27a Anticancer Drug
Sep 14, 2018
Sunshine Biopharma Announces $10 Million Equity Financing
Aug 16, 2018
Sunshine Biopharma Signs A Service Agreement With Utah Based Quintessential Biosciences Inc.
Jun 18, 2018
Sunshine Biopharma Launches Microbiology Testing Service
May 10, 2018
Sunshine Biopharma Annouces Extension Of The Term Of Its Brokered Up To $10 Million Private Placement Financing
Jan 04, 2018
Sunshine Biopharma Completes the Acquisition of Atlas Pharma
Sep 05, 2017
Sunshine Biopharma Enters Into An Investment Banking Agreement With Jitney Trade To Raise Up To $10 Million…
Jun 26, 2017
Sunshine Biopharma Releases Results of Independent Valuation
Jun 19, 2017
Sunshine Biopharma Files An Application With Health Canada For A Drug Establishment License
Jan 11, 2017
Sunshine Biopharma Currently Reviewing Twenty Three Additional Generic Products For In-licensing
Dec 09, 2016
Sunshine Biopharma Signs Strategic Alliance Agreement With Atlas Pharma
Jun 30, 2016
Sunshine Biopharma Signs Licensing Agreement For Three Additional Generic Products For Treatment Of Cancer And BPH
May 11, 2016
Sunshine Biopharma Signs Licensing Agreement For Anastrozole, The Company’s First Generic Drug For Treatment Of Breast Cancer
Mar 15, 2016
Sunshine Biopharma Eliminates The Debt Obligations Associated With The Recently Acquired Patents For It’s Adva-27a Anticancer Compound
Dec 28, 2015
Sunshine Biopharma Acquires All Remaining Worldwide Patents For Its Adva-27a Anticancer Compound
Oct 09, 2015
Sunshine Biopharma Acquires The US Patent For Its Anticancer Compound, Adva-27a
Aug 04, 2015
Sunshine Biopharma Announces That The Initial Manufacturing Sample Of Its Anticancer Compound Adva-27a…
May 26, 2015
Sunshine Biopharma To Receive This Week A Sample From The Adva-27a Manufacturing Currently Underway At Lonza In Switzerland
Mar 24, 2015
Sunshine Biopharma Announces Issuance Of Notice Of Allowance For The Patent Application Covering Adva-27a Anticancer Compound In India
Feb 25, 2015
Sunshine Biopharma Announces Change To Its Board Of Directors And Officers
Jan 20, 2015
Sunshine Biopharma Is Moving Forward With Its Development Plans For Adva-27a Anticancer Compound
Nov 19, 2014
Sunshine Biopharma Signs Agreement With Lonza To Manufacture Its Lead Anticancer Compound, Adva-27a
Nov 03, 2014
Ebola Virus Infections Could Potentially Be Treated With Sunshine Biopharma’s Lead Anticancer Compound, Adva-27a
Oct 14, 2014
Sunshine Biopharma Retains Renmark Financial Communications To Provide Investor Relations
Oct 01, 2014
Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Completes The Sop’s Required By Health Canada To Secure Drug Establishment License
Sep 03, 2014
Sunshine Biopharma Negotiating With Cro’s To Initiate Master Drug File For Adva-27a Anticancer Compound
Aug 21, 2014
Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Engages Health Canada Specialized Consultants To Secures Pharmaceutical…
Aug 11, 2014
Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Secures Dedicated Space To Commence Global Generic Pharmaceutical Operations
Jun 09, 2014
Sunshine Biopharma’s Adva-27a Featured In 2014 Worldwide Uterine Cancer Report For Its Effectiveness Against Multidrug Resistant Uterine Cancer Cells
May 12, 2014
Sunshine Biopharma Announces Issuance Of Notice Of Allowance For The Patent Application Covering Adva-27a Anticancer Compound In Canada
Apr 29, 2014
Sunshine Biopharma Secures Funding For Its Adva-27a Anticancer Compound From Dutchess Opportunity Fund II
Apr 07, 2014
Sunshine Biopharma Increases The Effectiveness Of Adva-27a Lead Compound 9.5-fold Against Breast And Pancreatic Cancer In Vitro
Mar 31, 2014
Management Of Sunshine Biopharma Alarmed By The Recent World Health Organization Report That Cancer Is On The Rise
Feb 14, 2014
Sunshine Biopharma Begins Construction Of Mouse Xenograft Models For Pancreatic Cancer To Advance Adva-27a…
Jun 19, 2013
Sunshine Biopharma’s Anticancer Drug Candidate, Adva-27a, Is Unaffected By The Recent Supreme Court Ruling
Jun 04, 2013
Sunshine Biopharma Announces That Its Breast Cancer Drug Candidate, Adva-27a, Also Destroys Pancreatic Cancer Cells
May 01, 2013
Sunshine Biopharma Narrows Kilogram Manufacturing Options For Adva-27a Breast Cancer Drug Candidate to Three Suppliers
Apr 09, 2013
Sunshine Biopharma HMEC Study Indicates Novel Anticancer Compound Adva-27a Non-Toxic at High Concentrations
Mar 14, 2013
Sunshine Biopharma Commences Negotiations with Contract Manufacturing Organizations for Production of its Multidrug-Resistant…
Feb 26, 2013
Sunshine Biopharma Reports on IND Research for its Novel Breast Cancer Drug Candidate, Adva-27a
Jan 15, 2013
Advanomics Corporation, The Parent Company of Sunshine Biopharma, Files A New Patent Application For Its Multidrug Resistance Adva-27a…
Dec 10, 2012
Sunshine Biopharma Completes Another IND-Enabling Study: Adva-27a Is Found To Be Effective Against Multidrug Resistant Uterine Cancer Cells
Dec 04, 2012
Sunshine Biopharma Completes Six IND-Enabling Studies for its Anticancer Compound, Adva-27a
Nov 27, 2012
Advanomics Corporation, The Parent Company of Sunshine Biopharma, Completes Acquisition of Adva-27a Patents
Nov 13, 2012
Sunshine Biopharma Initiates IND-Enabling Studies For Its Anticancer Compound, Adva-27a
Oct 09, 2012
Sunshine Biopharma Receives Scale-Up Manufacturing Protocol For Its Lead Anti-Cancer Compound, Adva-27a
Sep 25, 2012
Sunshine Biopharma’s Adva-27a Preclinical Research Results to be Published in Oct. Issue of ANTICANCER RESEARCH
Sep 20, 2012
Breast Cancer News: Geron Drug Fails, Herceptin® May Increase Heart Problems, Sunshine Biopharma Heading for Clinical Trials
Sep 13, 2012
Sunshine Biopharma Advances to Next Phase of Drug Development with Lead Anti-Cancer Compound, ADva-27a
Sep 04, 2012
Sunshine Biopharma Takes Delivery of Newly Manufactured Batch of Adva-27a and Proceeds to Conducting Biological Verification of…
Aug 15, 2012
Sunshine Biopharama Announces Submission of an Adva-27a Manuscript for Publication in a Peer-Reviewed Scientific Journal
Aug 03, 2012
BUYINS.NET Issues Sunshine Biopharma Squeeze Trigger Report
Jul 30, 2012
Sunshine Biopharma, Inc. (OTCBB: SBFM) – Targeting the Challenge of Multidrug Resistance in Breast and Lung Cancer by Developing Adva-27a
Jul 24, 2012
Biotech Investor Alert: CFO of Sunshine Biopharma Expands on Significance of Recent Manufacturing News of Lead Anti-Cancer Compound Adva-27a
Jul 19, 2012
Targeting Aggressive Forms of Cancer: Sunshine Biopharma (OTCBB:SBFM) and Roche (SIX: RO, ROG; OTCQX: RHHBY)
Jul 11, 2012
Sunshine Biopharma Engages Beta Pharma Canada For Manufacturing of an Initial Batch of Adva-27a
Jul 02, 2012
Biotech Investor Q&A with CFO of Sunshine Biopharma (OTCBB:SBFM) Discussing its Lead Compound – Adva-27a for Aggressive Forms of Cancer
Jun 26, 2012
Sunshine Biopharma’s Adva-27a Found to be Effective at Killing Multidrug Resistant Lung Cancer Cells
May 22, 2012
Pharmacokinetics Parameters of Sunshine Biopharma’s Lead Anti-Cancer Compound Exceed Expectations
Apr 09, 2012
Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering its Adva-27a Anti-Cancer Compound
Mar 26, 2012
Sunshine Biopharma and Binghamton University to Present New Data at the Upcoming American Association for Cancer Research Meeting in Chicago
Nov 28, 2011
Avastin Ousted by FDA for Breast Cancer, Sunshine Biopharma Gears-Up for Clinicals
Nov 15, 2011
Sunshine Biopharma’s Announces Successful Completion of Preclinical Studies for Adva-27a, The Company’s Lead Anti-Cancer Compound
Oct 05, 2011
Sunshine Biopharma’s Anti-Cancer Compound, Adva-27a, found to be a Topoisomerase II Inhibitor
Aug 30, 2011
Clearance of Sunshine Biopharma’s Anti-Cancer Compound, Adva-27a, Does Not Involve a Toxic Intermediate
Jul 27, 2011
Sunshine Biopharma Looking to Mimic Roche’s Billion Dollar Cancer Drug Success
Jul 25, 2011
Sunshine Biopharma’s Lead Anti-tumor Compound, Adva-27a, is cleared via a cytochrome P450-Independent Mechanism
Jul 11, 2011
Sunshine Biopharma’s Adva-27a is 16-times more effective at killing multidrug resistant breast cancer cells
Jun 17, 2011
Sunshine Biopharma enters into clinical trials agreement with the Jewish General Hospital in Montreal, Canada
Apr 01, 2011
Sunshine Biopharma’s CEO Does Live Interview on ChartPoppers.com
Mar 27, 2011
Sunshine Biopharma’s Lead Anti-Cancer Compound, Adva-27a, performs exceptionally well in human microsome stability assays
Mar 04, 2011
CEO CFO Interviews Dr. Steve N. Slilaty
Feb 25, 2011
Interview with Central NY Business Journal
Jan 26, 2011
FOX 40 WICZ.COM Interview of Binghamton University on Sunshine BioPharma Part 1
Jan 21, 2011
Sunshine Biopharma And Binghamton University (State University Of New York) Enter Into Research Agreement
Oct 26, 2010
CEOCAST Interview with Dr. Steve Slilaty of Sunshine BioPharma Inc.
Oct 13, 2010
Sunshine Biopharma, Inc. Begins Drug Development Activities
Oct 20, 2009
Mountain West Business Solutions Acquires Sunshine Biopharma